PSMB9 and non-small cell lung carcinoma: A small group study found high PSMB9 levels related to durable clinical benefit after anti-PD1 treatment in non-small-cell lung cancers (NSCLCs) [11], suggesting that PSMB9 could serve as a predictive biomarker for identifying patients likely to benefit from immunotherapy.